As of Aug 31
| -0.53 / -1.47%|
The 3 analysts offering 12-month price forecasts for Anika Therapeutics Inc have a median target of 51.00, with a high estimate of 57.00 and a low estimate of 47.00. The median estimate represents a +44.03% increase from the last price of 35.41.
The current consensus among 4 polled investment analysts is to Buy stock in Anika Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.